Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Praxis Precision Medicines reports progress in Q2 2024 earnings call

Praxis Precision Medicines delivered a solid performance in Q2 2024, with progress on key clinical programs and a healthy financial position. While facing challenges in managing expenses and meeting regulatory requirements, the company remains optimistic about future milestones. Opportunities lie in leveraging potential drug approvals and advancing innovative therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Aligos Therapeutics

Array Technologies

Codiak Biosciences

Eastern Bankshares, Inc.

Opthea

Tarsus Pharmaceuticals

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Praxis. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Praxis, are expected to be approximately $190.0 million. Praxis has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering

Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders now looks to raise up to $180.0 million. The company disclosed that it is now offering 10.0 million shares, up from the 7.4 million shares it said it was offering last week.

Praxis Precision Medicines upsizes IPO by 35%, now looks to raise up to $180 million

Praxis Precision Medicines has filed proposed terms for its U.S. IPO.

Praxis Precision Medicines Readies $126 Million IPO

Praxis Precision Medicines Inc. set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders looks to raise up to $133.2 million. The company is offering 7.4 million shares in the IPO, which is expected to price between $16 and $18 a share.

Praxis Precision sets IPO terms, to be valued at up to $615 million

News for Praxis Precision Medicines Stock (PRAX)